Jyske Bank
Share repurchase programme: Transactions of week 13 2025
Share repurchase programme: Transactions of week 13 2025
The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the "Safe Harbour Rules").
The following transactions have been made under the program:
Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
Accumulated, previous announcement | 71,716 | 581.53 | 41,705,310 |
24 March 2025 | 3,909 | 587.82 | 2,297,802 |
25 March 2025 | 3,871 | 595.04 | 2,303,389 |
26 March 2025 | 49,692 | 572.47 | 28,446,961 |
27 March 2025 | 46,217 | 569.76 | 26,332,422 |
28 March 2025 | 45,592 | 559.11 | 25,490,975 |
Accumulated under the programme | 220,997 | 572.75 | 126,576,859 |
Following settlement of the transactions stated above, Jyske Bank will own a total of 2,986,115 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 4.65% of the share capital.
Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
Yours faithfully,
Jyske Bank
Contact: Birger Krøgh Nielsen, CFO, tel. +45 89 89 64 44.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG3.4.2025 02:13:00 CEST | Press release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
CRUSHON AI CORP3.4.2025 02:05:57 CEST | Press release
Crushon AI Adds Target Play for Spicy AI and NSFW Character Chats
Appian Capital Advisory2.4.2025 22:34:00 CEST | Press release
Appian completes sale of MVV to Baiyin Nonferrous for US$420 million
Nokia Oyj2.4.2025 21:45:00 CEST | Press release
Nokia completes the share buyback program launched in November 2024
Nokia Oyj2.4.2025 21:30:00 CEST | Press release
Nokia Corporation: Repurchase of own shares on 02.04.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom